This preview shows page 1. Sign up to view the full content.
Unformatted text preview: Services has projected that the premiums would stabilize at $24 a month. However, Oversight Investigators state that brand name drugs are so much higher than generics that their cost increases will overshadow the savings from generics. The programs costs still remain well below initial projections, and experts say that six months of data is not enough to make a conclusive decision about the effectiveness of the program. Ken Johnson, senior vice president of PhRMA, the drug manufacturers lobby, states that the new program is saving money overall for both taxpayers and seniors. Though prices may be increasing somewhat, the consumers wont be terribly affected by the price increases....
View Full Document
- Spring '08